Source comparison
PT-141 50s Age Specific Protocol: Dosing vs PDE5 Inhibitors
Mechanism Melanocortin receptor agonist (central + peripheral arousal) PDE5 inhibitor (penile/clitoral blood flow only) PDE5 inhibitor (extended half-life) PT-141 bypasses vascular insufficiency. Effective when blood flow is not the limiting factor Onset Time
This comparison does not assign a generated winner or score.
- Mechanism
- Melanocortin receptor agonist (central + peripheral arousal)
- PDE5 inhibitor (penile/clitoral blood flow only)
- PDE5 inhibitor (extended half-life)
- PT-141 bypasses vascular insufficiency. Effective when blood flow is not the limiting factor
- Onset Time
- 60–90 minutes
- 30–60 minutes
- 60–120 minutes
- PT-141 slower onset but does not require sexual stimulation to activate
- Duration
- 6–12 hours
- 4–6 hours
- 24–36 hours
- Tadalafil longest duration, but PT-141 produces spontaneous arousal independent of external cues
- Cardiovascular Risk (Age 50+)
- Transient hypertension 15–25 mmHg; avoid if uncontrolled HTN
- Hypotension risk if concurrent nitrates; safe if BP controlled
- Same as sildenafil
- PT-141 raises BP transiently; PDE5 inhibitors lower BP. Opposite cardiovascular profiles
- Efficacy in Vascular Insufficiency
- High (mechanism independent of blood flow)
- Moderate (requires functional arterial response)
- PT-141 superior when arterial compliance is significantly reduced
- Nausea Incidence
- 40–50% initial doses, resolves by dose 4
- <5%
- PT-141 nausea is temporary; antiemetic prophylaxis eliminates it